1. Market Research
  2. > Viral Infections - Pipeline Review, H2 2013

Viral Infections - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 170 pages

Viral Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Viral Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Viral Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Viral Infections. Viral Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Viral Infections.
- A review of the Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Viral Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Viral Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Viral Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Viral Infections - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Viral Infections Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Viral Infections 10
Viral Infections Therapeutics under Development by Companies 12
Viral Infections Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Viral Infections Therapeutics - Products under Development by Companies 21
Viral Infections Therapeutics - Products under Investigation by Universities/Institutes 25
Companies Involved in Viral Infections Therapeutics Development 26
Baxter International Inc. 26
Johnson and Johnson 27
United Therapeutics Corporation 28
Nektar Therapeutics 29
MedImmune LLC 30
Isis Pharmaceuticals, Inc. 31
Bioneer Corporation 32
Nanotherapeutics, Inc. 33
Santaris Pharma A/S 34
AVI BioPharma Inc. 35
4SC AG 36
Evotec Aktiengesellschaft 37
Hemispherx Biopharma, Inc. 38
Lupin Limited 39
NanoViricides, Inc. 40
Pevion Biotech Ltd 41
Alnylam Pharmaceuticals, Inc 42
BioCryst Pharmaceuticals, Inc. 43
SIGA Technologies, Inc. 44
Tolerx, Inc. 45
Summit Corporation plc 46
Digna Biotech, S.L. 47
Functional Genetics, Inc. 48
Chipscreen Biosciences Ltd 49
LigoCyte Pharmaceuticals, Inc. 50
Evolva SA 51
ActoKine Therapeutics 52
Oncodesign SA 53
Cellectis S.A. 54
AiCuris GmbH and Co. KG 55
AlphaVax, Inc. 56
PTC Therapeutics, Inc. 57
Kineta, Inc. 58
Chimerix, Inc. 59
Biotica Technology Ltd 60
Epiphany Biosciences, Inc. 61
Oncovir, Inc. 62
Ascenion GmbH 63
AvidBiotics Corp. 64
TSRL, Inc. 65
Medical Enzymes AG 66
SelectX Pharmaceuticals, Inc. 67
Polaris Group 68
Viral Infections - Therapeutics Assessment 69
Assessment by Monotherapy Products 69
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 75
4SC-206 - Drug Profile 75
CSO-240-0600 - Drug Profile 76
Extra Domain A - Drug Profile 77
GelVac - Drug Profile 78
cidofovir - Drug Profile 79
Oragen - Drug Profile 80
Glycobiology Antiviral Agents - Drug Profile 81
ST-669 - Drug Profile 82
Vaccine For Filovirus - Drug Profile 83
GlutaChemo - Drug Profile 84
EV-009 - Drug Profile 85
TRX-385 - Drug Profile 86
AVI-7012 - Drug Profile 87
ADIF-Base-I - Drug Profile 88
ADI-PEG20 - Drug Profile 89
4SC-301 - Drug Profile 92
TRX-585 - Drug Profile 93
EPB-200 - Drug Profile 94
Human Parainfluenza Type 3 Virus Vaccine - Drug Profile 95
SMT-15000 - Drug Profile 97
Antiviral Program - Drug Profile 98
Broad Spectrum Antiviral - Drug Profile 99
Fve Polypeptide - Drug Profile 100
Drug For Viral Diseases - Drug Profile 101
rOAS-1 - Drug Profile 102
FGI-110 - Drug Profile 103
Vaccines for Viral Infection - Drug Profile 104
Ross River Virus Vaccine - Drug Profile 105
Anti Viral Program - Drug Profile 106
Drug For Bunya Virus - Drug Profile 107
HB-101 - Drug Profile 108
Anti-Viral Program - Drug Profile 109
BCX-4430 - Drug Profile 110
TSR-087 - Drug Profile 111
TSR-505 - Drug Profile 112
Recombinant Vesicular Stomatitis Virus - Drug Profile 113
Virus-Similar Particle Vaccine - Drug Profile 114
Eglin C Variants - Drug Profile 115
Lipovir - Drug Profile 116
Drug For Viral Infections - Drug Profile 117
Etnangien - Drug Profile 118
LPS Neutralizing Peptides - Drug Profile 119
DIS-BIO-VIR - Drug Profile 120
Antibody For Viral Liver Cirrhosis - Drug Profile 121
PEV-10 - Drug Profile 122
ISIS-GSK3 - Drug Profile 123
Antiviral Cytokine - Drug Profile 124
Poly-ICLC - Drug Profile 125
Dual Active Cytomegalovirus (CMV)/Polyomavirus BK (BKV) Program - Drug Profile 127
RV-1088 - Drug Profile 128
Antiviral Program - Drug Profile 129
Antiviral Program - Drug Profile 130
Thionucleoside Drugs - Drug Profile 131
MAb Against RSV And MPV - Drug Profile 132
MAb Against JCV And BKV - Drug Profile 133
IKT-014 - Drug Profile 134
Belactosin Derivatives - Drug Profile 135
Salinosporamide Derivatives - Drug Profile 136
Omuralide Derivatives - Drug Profile 137
AK-2 - Drug Profile 138
Drug For Viral Infections - Drug Profile 139
DEF-201 - Drug Profile 140
Cell-Division Cycle Protein-Like Kinase Family Inhibitor - Drug Profile 142
Dendritic Cell Vaccine - Drug Profile 143
Nuclear Export Inhibitors - Drug Profile 144
Griffithsin - Drug Profile 145
BA-368 - Drug Profile 146
Anti-NoroVirus Monoclonal Antibody - Drug Profile 147
Short Chain Fatty Acid Hybrid Compounds - Drug Profile 148
Anti-Viral Therapy - Drug Profile 149
VSF - Drug Profile 150
Viral Infections Therapeutics - Drug Profile Updates 151
Viral Infections Therapeutics - Discontinued Products 155
Viral Infections Therapeutics - Dormant Products 156
Viral Infections - Product Development Milestones 157
Featured News and Press Releases 157
Appendix 164
Methodology 164
Coverage 164
Secondary Research 164
Primary Research 164
Expert Panel Validation 164
Contact Us 165
Disclaimer 165



List of Tables

Number of Products Under Development for Viral Infections, H2 2013 15
Products under Development for Viral Infections - Comparative Analysis, H2 2013 16
Number of Products under Development by Companies, H2 2013 18
Number of Products under Development by Companies, H2 2013 (Contd..1) 19
Number of Products under Development by Companies, H2 2013 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2013 22
Comparative Analysis by Late Stage Development, H2 2013 23
Comparative Analysis by Early Clinical Stage Development, H2 2013 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 25
Products under Development by Companies, H2 2013 26
Products under Development by Companies, H2 2013 (Contd..1) 27
Products under Development by Companies, H2 2013 (Contd..2) 28
Products under Development by Companies, H2 2013 (Contd..3) 29
Products under Investigation by Universities/Institutes, H2 2013 30
Baxter International Inc., H2 2013 31
Johnson and Johnson, H2 2013 32
United Therapeutics Corporation, H2 2013 33
Nektar Therapeutics, H2 2013 34
MedImmune LLC, H2 2013 35
Isis Pharmaceuticals, Inc., H2 2013 36
Bioneer Corporation, H2 2013 37
Nanotherapeutics, Inc., H2 2013 38
Santaris Pharma A/S, H2 2013 39
AVI BioPharma Inc., H2 2013 40
4SC AG, H2 2013 41
Evotec Aktiengesellschaft, H2 2013 42
Hemispherx Biopharma, Inc., H2 2013 43
Lupin Limited, H2 2013 44
NanoViricides, Inc., H2 2013 45
Pevion Biotech Ltd, H2 2013 46
Alnylam Pharmaceuticals, Inc, H2 2013 47
BioCryst Pharmaceuticals, Inc., H2 2013 48
SIGA Technologies, Inc., H2 2013 49
Tolerx, Inc., H2 2013 50
Summit Corporation plc, H2 2013 51
Digna Biotech, S.L., H2 2013 52
Functional Genetics, Inc., H2 2013 53
Chipscreen Biosciences Ltd, H2 2013 54
LigoCyte Pharmaceuticals, Inc., H2 2013 55
Evolva SA, H2 2013 56
ActoKine Therapeutics, H2 2013 57
Oncodesign SA, H2 2013 58
Cellectis S.A., H2 2013 59
AiCuris GmbH and Co. KG, H2 2013 60
AlphaVax, Inc., H2 2013 61
PTC Therapeutics, Inc., H2 2013 62
Kineta, Inc., H2 2013 63
Chimerix, Inc., H2 2013 64
Biotica Technology Ltd, H2 2013 65
Epiphany Biosciences, Inc., H2 2013 66
Oncovir, Inc., H2 2013 67
Ascenion GmbH, H2 2013 68
AvidBiotics Corp., H2 2013 69
TSRL, Inc., H2 2013 70
Medical Enzymes AG, H2 2013 71
SelectX Pharmaceuticals, Inc., H2 2013 72
Polaris Group, H2 2013 73
Assessment by Monotherapy Products, H2 2013 74
Assessment by Stage and Route of Administration, H2 2013 76
Assessment by Stage and Molecule Type, H2 2013 79
Viral Infections Therapeutics - Drug Profile Updates 156
Viral Infections Therapeutics - Discontinued Products 160
Viral Infections Therapeutics - Dormant Products 161



List of Figures

Number of Products under Development for Viral Infections, H2 2013 15
Products under Development for Viral Infections - Comparative Analysis, H2 2013 16
Products under Development by Companies, H2 2013 17
Products under Investigation by Universities/Institutes, H2 2013 21
Late Stage Products, H2 2013 23
Early Clinical Stage Products, H2 2013 24
Discovery and Pre-Clinical Stage Products, H2 2013 25
Assessment by Monotherapy Products, H2 2013 74
Assessment by Route of Administration, H2 2013 75
Assessment by Stage and Route of Administration, H2 2013 76
Assessment by Molecule Type, H2 2013 77
Assessment by Stage and Molecule Type, H2 2013 78



Companies Mentioned

Baxter International Inc.
Johnson and Johnson
United Therapeutics Corporation
Nektar Therapeutics
MedImmune LLC
Isis Pharmaceuticals, Inc.
Bioneer Corporation
Nanotherapeutics, Inc.
Santaris Pharma A/S
AVI BioPharma Inc.
4SC AG
Evotec Aktiengesellschaft
Hemispherx Biopharma, Inc.
Lupin Limited
NanoViricides, Inc.
Pevion Biotech Ltd
Alnylam Pharmaceuticals, Inc
BioCryst Pharmaceuticals, Inc.
SIGA Technologies, Inc.
Tolerx, Inc.
Summit Corporation plc
Digna Biotech, S.L.
Functional Genetics, Inc.
Chipscreen Biosciences Ltd
LigoCyte Pharmaceuticals, Inc.
Evolva SA
ActoKine Therapeutics
Oncodesign SA
Cellectis S.A.
AiCuris GmbH and Co. KG
AlphaVax, Inc.
PTC Therapeutics, Inc.
Kineta, Inc.
Chimerix, Inc.
Biotica Technology Ltd
Epiphany Biosciences, Inc.
Oncovir, Inc.
Ascenion GmbH
AvidBiotics Corp.
TSRL, Inc.
Medical Enzymes AG
SelectX Pharmaceuticals, Inc.
Polaris Group

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.